

DESCRIPTION

Source Mouse myeloma cell line, NS0-derived human CD155/PVR protein
Gly27-Asn343, with a C-terminal 6-His tag
Accession # AHH15542.1

N-terminal Sequence Analysis Gly27

Structure / Form Biotinylated via amines

Predicted Molecular Mass 35 kDa

SPECIFICATIONS

SDS-PAGE 60-70 kDa, under reducing conditions.

Activity Measured by its binding ability in a functional ELISA.
Biotinylated Recombinant Human CD155/PVR His-tag (Catalog # BT2530) binds Recombinant Human TIGIT (A103) Fc Chimera (Catalog # 7898-TGB) with an ED₅₀ of 4.00-60.0 ng/mL.

Endotoxin Level <0.10 EU per 1 µg of the protein by the LAL method.

Purity >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Formulation Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution Reconstitute at 250 µg/mL in water.


Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.


DATA

Binding Activity



Biotinylated Recombinant Human CD155/PVR His-tag Protein Binding Activity. Biotinylated Recombinant Human CD155/PVR His-tag Protein (Catalog # BT2530) binds Recombinant Human TIGIT (A103) Fc Chimera (Catalog # 7898-TGB) with an ED₅₀ of 4.00-60.0 ng/mL.

SDS-PAGE



Biotinylated Recombinant Human CD155/PVR His-tag Protein SDS-PAGE. 2 µg/lane of Biotinylated Recombinant Human CD155/PVR His-tag Protein (Catalog # BT2530) was resolved with SDS-PAGE under reducing (R) condition and visualized by Coomassie® Blue staining, showing bands at 60-70 kDa.

BACKGROUND

CD155, also known as PVR (poliovirus receptor), Nectin-5 (nectin-like molecule-5) and, in rodents, TAGE4 (tumor-associated glycoprotein E4), is a 70 kDa type I transmembrane glycoprotein in the nectin-related family of adhesion proteins within the immunoglobulin superfamily (1, 2). CD155 binds other molecules including Vitronectin, Nectin-3, DNAM-1/CD226, CD96, and TIGIT but does not bind homotypically (3). Mature human CD155 consists of a 323 amino acid (aa) extracellular domain (ECD) with one N-terminal V-type and two C2-type Ig-like domains, a 24 aa transmembrane segment, and a 50 aa cytoplasmic tail. Within the ECD, human CD155 shares 45% aa sequence identity with mouse and rat CD155, and 52% with human Nectin-2. The V-type domain of CD155 mediates all binding, including to polio virus (1), and alternative splicing within this domain in humans can modulate ligand binding (4). Human CD155 can also be spliced to generate secreted isoforms (5). CD155 is up-regulated on endothelial cells by IFN- γ and is highly expressed on immature thymocytes, lymph node dendritic cells, and tumor cells of epithelial and neuronal origin (1, 2, 6-9). It is preferentially expressed on Th17 cells compared to Th2 cells (10), and its activation promotes the development of Th1 responses (11). On migrating cells, CD155 is concentrated at the leading edge, where it binds basement membrane Vitronectin, recruits Nectin-3-expressing cells, and cooperates with PDGF and Integrin $\alpha\beta 3$ to promote cell migration (1, 3, 12). Enhanced CD155 expression in tumor cells contributes to loss of contact inhibition and increased migration but also allows tumor cell recognition and killing by DNAM-1 or CD96 expressing NK cells (1, 7, 13). Binding of monocyte DNAM-1 to endothelial cell CD155 promotes transendothelial migration (8). The expression of CD155 on mouse CD8 $^{+}$ thymocytes prevents their premature exit from the thymus (14). Within intestinal Peyer's patches, follicular dendritic cell CD155 activates follicular helper T cells via DNAM-1 or CD96 binding (7-9, 15). CD155 also binds the inhibitory ligand TIGIT on NK and some mature T cells, antagonizing DNAM-1 effects (7, 15, 16).

References:

1. Mandai, K. *et al.* (2015) *Curr. Top. Dev. Biol.* **112**:197.
2. Mendelsohn, C.L. *et al.* (1989) *Cell* **56**:855.
3. Sato, T. *et al.* (2004) *Genes to Cells* **9**:791.
4. Meyer, D. *et al.* (2009) *J. Biol. Chem.* **284**:2235.
5. Koike, S. *et al.* (1990) *EMBO J.* **9**:3217.
6. Escalante, N.K. *et al.* (2011) *Arterioscler. Thromb. Vasc. Biol.* **31**:1177.
7. Xu, Z. and B. Jin (2010) *Cell. Mol. Immunol.* **7**:11.
8. Reymond, N. *et al.* (2004) *J. Exp. Med.* **199**:1331.
9. Maier, M.K. *et al.* (2007) *Eur. J. Immunol.* **37**:2214.
10. Lozano, E. *et al.* (2013) *J. Immunol.* **191**:3673.
11. Yamashita-Kanemaru, Y. *et al.* (2015) *J. Immunol.* **194**:5644.
12. Mueller, S. and E. Wimmer (2003) *J. Biol. Chem.* **278**:31251.
13. Chan, C.J. *et al.* (2010) *J. Immunol.* **184**:902.
14. Qui, Q. *et al.* (2010) *J. Immunol.* **184**:1681.
15. Seth, S. *et al.* (2009) *Eur. J. Immunol.* **39**:3160.
16. Stanitsky, N. *et al.* (2009) *Proc. Natl. Acad. Sci. USA* **106**:17858.